Ultra-selective radiation segmentectomy for early-stage hepatocellular carcinoma
This study demonstrates that ultra-selective radiation segmentectomy (uRS) with glass <sup>90</sup>Y microspheres can achieve high rates of complete imaging and pathologic response in early-stage HCC while treating very small liver volumes. These results replicate and extend prior radiation segmentectomy studies, underscoring that the ablative potential of <sup>90</sup>Y can be maintained with even greater liver parenchymal preservation. These findings are important for patients who are not candidates for surgery or ablation, especially given low rates of liver function decline after uRS. In practice, uRS may serve as a definitive therapy or as a bridge to liver transplantation, while voxel-based dosimetry provides a framework for ensuring adequate tumor coverage and identifying incomplete responders.
Authors
- Maria B. Majella Doyle
- N. Mani (ORCID: https://orcid.org/0000-0003-0700-8171)
- Guilherme Emílio Ferreira (ORCID: https://orcid.org/0000-0002-3966-4846)
- Darren R. Cullinan (ORCID: https://orcid.org/0000-0002-9161-212X)
- Benjamin Tan (ORCID: https://orcid.org/0000-0003-1838-1182)
- Kevin Korenblat (ORCID: https://orcid.org/0000-0002-7912-8191)
- John Karageorgiou (ORCID: https://orcid.org/0000-0002-4966-1139)
- Joseph Daniel Giardina (ORCID: https://orcid.org/0000-0002-7479-1277)
- William C. Chapman (ORCID: https://orcid.org/0000-0002-7602-5445)
- Tharun T. Alamuri (ORCID: https://orcid.org/0000-0002-8765-3498)
- M.A. Thomas (ORCID: https://orcid.org/0000-0002-3533-740X)
- Daniel A. Braga
- C. Malone (ORCID: https://orcid.org/0000-0003-4111-9123)
- Sam Meiselman
Institutions
- Washington University in St. Louis (US)
- Stony Brook School (US)
- Mallinckrodt (United States) (US)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101636
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32
Funders
- AstraZeneca
- Boston Scientific Corporation
- Eisai